Marksans Pharma Limited announced the successful completion of its acquisition of 100% share capital in QliniQ B.V., a Netherlands-based entity. This strategic move was confirmed on June 16, 2026, following their prior communication on June 1, 2026. The company has finalized all processes related to this significant international acquisition.
Acquisition Finalized
Marksans Pharma Limited has officially confirmed the completion of its acquisition process for 100% of the share capital of QliniQ B.V. This Netherlands-based company is now fully integrated into Marksans Pharma’s operations. The announcement was made on June 16, 2026, providing an update subsequent to the company’s initial letter dated June 1, 2026, regarding this transaction.
Source: BSE
